Addiction med faces competition

Indivior will cut about 130 jobs as part of its decision to discontinue sales for a schizophrenia drug – and adjusted its financial outlook for the 2nd quarter and full year, due to adverse market dynamics affecting Sublocade (buprenorphine) growth and commercial uptake of Opvee (nalmefene).